Table 2 Major changes obtained in haematology and coagulation measurements (group mean values ± standard deviation) in male and female rats treated intravenously for 4 weeks and 2 weeks of recovery period with 0 (vehicle = 0.9% saline solution), 5, 9 and 15 mg/kg/day of SET-M33 peptide.

From: Safety evaluations of a synthetic antimicrobial peptide administered intravenously in rats and dogs

Sex	Dose (mg/kg/day)	Haematology and coagulation week 4 of treatment—Group mean values
Sex	Dose (mg/kg/day)	Hct (L/L)	Hb (g/dL)	RBC (× 10¹²/L)	Retic (× 10¹²/L)	Retic (%)	MCH (pg)	MCHC (g/dL)	MCV (fL)	WBC (× 10⁹/L)	HDW (g/dL)	L (× 10⁹/L)	LUC (× 10⁹/L)	Plt (× 10⁹/L)	SPT (sec)	SAPT (sec)
Male	0	0.454 ± 0.0145	15.3 ± 0.45	8.49 ± 0.32	0.139 ± 0.0233	1.64 ± 0.253	18.00 ± 0.49	33.70 ± 0.71	53.50 ± 0.79	10.00 ± 1.761	2.94 ± 0.097	8.67 ± 1.283	0.08 ± 0.022	779 ± 143.1	23.0 ± 6.54	37.6 ± 5.65
	5	0.401** ± 0.0198	13.5** ± 0.48	7.55** ± 0.306	0.152 ± 0.0283	2.00* ± 0.352	17.90 ± 0.38	33.80 ± 0.76	53.00 ± 1.15	10.76 ± 1.713	3.21** ± 0.126	9.73 ± 1.418	0.08 ± 0.027	917* ± 95.4	21.8 ± 0.82	36.5 ± 6.18
	9	0.348** ± 0.0275	11.9** ± 0.84	6.81** ± 0.538	0.076** ± 0.0292	1.10** ± 0.357	17.40* ± 0.39	34.20 ± 0.73	51.0** ± 1.71	11.36 ± 2.206	3.30** ± 0.174	10.30 ± 2.104	0.10 ± 0.049	923* ± 148.7	24.1** ± 0.68	31.6* ± 5.31
	15	0.311** ± 0.0158	10.7** ± 0.58	6.15** ± 0.322	0.037** ± 0.0091	0.60** ± 0.160	17.50* ± 0.47	34.6** ± 0.50	50.50** ± 0.77	13.51** ± 2.506	3.23** ± 0.151	12.35** ± 2.216	0.14** ± 0.053	961** ± 130.1	24.5** ± 1.05	31.9* ± 5.11
Female	0	0.416 ± 0.0133	14.1 ± 0.47	7.62 ± 0.23	0.176 ± 0.0445	2.31 ± 0.52	18.50 ± 0.40	33.80 ± 0.73	54.70 ± 1.64	7.30 ± 2.064	2.76 ± 0.096	6.25 ± 2.013	0.05 ± 0.023	853 ± 204.900	21.9 ± 1.150	37.0 ± 5.260
	5	0.382** ± 0.0127	12.9** ± 0.46	7.11** ± 0.291	0.180 ± 0.0473	2.55 ± 0.712	18.20 ± 0.40	33.90 ± 0.43	53.70 ± 0.91	7.11 ± 0.596	2.92 ± 0.127	6.31 ± 0.710	0.05 ± 0.011	1004* ± 115.600	21.9 ± 0.660	33.1 ± 5.900
	9	0.352** ± 0.0199	12.0** ± 0.48	6.61** ± 0.358	0.112** ± 0.0462	1.69* ± 0.646	18.10 ± 0.43	34.00 ± 0.80	53.30* ± 0.76	9.15 ± 2.982	3.34** ± 0.189	7.91 ± 2.475	0.08** ± 0.038	1075** ± 136.70	23.6** ± 1.00	26.7** ± 3.890
	15	0.284** ± 0.0223	9.7** ± 0.75	5.44** ± 0.488	0.060** ± 0.0162	1.12** ± 0.345	17.9** ± 0.48	34.20 ± 0.33	52.3** ± 1.44	10.34** ± 1.917	2.99** ± 0.199	9.22** ± 1.713	0.09** ± 0.019	1250** ± 181.00	23.3** ± 1.270	25.6** ± 5.910

Sex	Dose (mg/kg/day)	Haematology and coagulation week 2 of recovery—Group mean values
Sex	Dose (mg/kg/day)	Hct (L/L)	Hb (g/dL)	RBC (× 10¹²/L)	Retic (× 10¹²/L)	Retic (%)	MCH (pg)	MCHC (g/dL)	MCV (fL)	WBC (× 10⁹/L)	HDW (g/dL)	L (× 10⁹/L)	LUC (× 10⁹/L)	Plt (× 10⁹/L)	SPT (sec)	SAPT (sec)
Male	0	0.450 ± 0.0136	15.2 ± 0.4	8.73 ± 0.359	0.122 ± 0.0091	1.40 ± 0.13	17.4 ± 0.61	33.8 ± 0.74	51.6 ± 0.8	9.86 ± 1.818	3.03 ± 0.075	8.39 ± 1.371	0.08 ± 0.026	722 ± 58.2	21.5 ± 0.63	20.3 ± 3.44
Male	15	0.262** ± 0.0197	9.5** ± 0.55	5.36** ± 0.37	0.061* ± 0.412	1.1 ± 0.797	17.7 ± 0.47	36.1** ± 0.98	49.0 ± 2.37	6.84* ± 1.913	3.25* ± 0.16	6.12 ± 1.655	0.05 ± 0.034	919* ± 169.1	21.1 ± 0.67	13.3* ± 3.41
Female	0	0.431 ± 0.0097	15 ± 0.29	8.04 ± 0.097	0.083 ± 0.0311	1.03 ± 0.385	18.7 ± 0.29	34.9 ± 0.31	53.6 ± 1.07	7.47 ± 1.792	2.64 ± 0.102	6.16 ± 1.375	0.06 ± 0.014	81 ± 135	22.4 ± 0.33	20.4 ± 1.8
Female	15	0.268** ± 0.0087	9.3** ± 0.34	5.31** ± 0.139	0.063 ± 0.0254	1.17 ± 0.458	17.5** ± 0.62	34.7 ± 0.5	50.6** ± 1.15	7.89 ± 1.712	3.04** ± 0.167	6.58 ± 1.708	0.05 ± 0.018	1208** ± 106.8	22.9 ± 0.79	16.8* ± 1.37

Hct haematocrit, Hb haemoglobin, RBC erythrocyte count, Retic reticulocyte count (absolute and relative), MCH mean corpuscular haemoglobin, MCHC mean corpuscular haemoglobin concentration, MCV mean corpuscular volume, WBC leukocyte count, total, HDW haemoglobin concentration distribution width, L lymphocytes, LUC large unstained cells, Plt platelet (thrombocyte) count, SPT prothrombin time, SAPT activated partial thromboplastin time.
Significant differences between peptide vs. control groups were expressed at the 5% (*p < 0.05) or 1% (**p < 0.01) level. For statistical analysis, Dunnett, Shirley’ Williams, Wilcoxon and t tests were used.

Back to article page

Table 2 Major changes obtained in haematology and coagulation measurements (group mean values ± standard deviation) in male and female rats treated intravenously for 4 weeks and 2 weeks of recovery period with 0 (vehicle = 0.9% saline solution), 5, 9 and 15 mg/kg/day of SET-M33 peptide.

Search

Quick links